Highlights

  • Fisher & Paykel Healthcare develops medical devices and systems for respiratory and acute care.
  • FY26 operating revenue totalled $2.31 billion, up 14% year on year.
  • FY26 net profit after tax was $468.5 million, a rise of 24%.
  • Hospital product group revenue was $1.51 billion, increasing 18%.

Fisher & Paykel Healthcare Corporation Limited designs and manufactures medical devices and systems for respiratory care, acute care and surgery. Its results for the financial year ended 31 March 2026 provide a recent financial view of hospital therapies, consumables and overall group profitability.

Medical Device Operations and FY26 Revenue

Fisher & Paykel Healthcare (ASX:FPH) reported FY26 operating revenue of $2.31 billion, 14% above the previous financial year, or 12% higher on a constant-currency basis. Reported net profit after tax reached $468.5 million, rising 24% year on year, or 28% in constant currency. The company published these figures in its May 2026 full-year results announcement.

Hospital Business and Consumables

The Hospital product group generated revenue of $1.51 billion in FY26, an increase of 18% from the prior financial year. On a constant-currency basis, the increase was 15%. This business includes products used in respiratory, acute and surgical care, making it a material contributor to group revenue.

Fisher & Paykel Healthcare (ASX:FPH) also reported that hospital consumables sales increased 16% in reported currency and 14% in constant currency. Consumables represent products used in the course of clinical treatment, while the broader product group also includes associated technologies. The separate figures help describe activity within the hospital business without treating every product category as identical.

Reporting Calendar and Financial Measures

The company’s FY26 reporting period ended on 31 March 2026, and the annual result was released on 26 May. Its published financial calendar identifies 30 September 2026 as the end of the first half of its following financial year, with an interim results announcement scheduled for November 2026.

Fisher & Paykel Healthcare (ASX:FPH) reports both headline and constant-currency growth figures. The latter removes the effect of exchange-rate changes when comparing reporting periods. Using both figures provides a clearer description of how group and hospital revenue changed, without implying that currency-adjusted and statutory figures are interchangeable.

Hospital consumables revenue increased during FY26 even as the company noted subdued seasonal respiratory illness admissions in several major markets compared with the preceding year. Fisher & Paykel Healthcare (ASX:FPH) attributed performance to activity across hospital therapies. That commentary is a company explanation of its reported result, not an independently determined forecast of hospital demand in subsequent periods.

The May release identified the Hospital product group as one of the company’s major reporting categories. The reported annual group revenue and Hospital revenue measure different levels of the business: the former includes all group activities, whereas the latter refers to one segment. Fisher & Paykel Healthcare (ASX:FPH) also provided a reported-currency figure and a constant-currency comparison for each relevant growth rate. As a result, the figures should be retained with their correct categories and periods rather than aggregated or used as substitutes for one another across reporting periods.

Key Insights

Fisher & Paykel Healthcare (ASX:FPH) reported higher FY26 revenue and profit alongside increased hospital product and consumables sales. The figures cover the year ended March 2026, while the next interim results relate to a different reporting period. The company’s two growth measures, reported and constant currency, should be read according to their stated definitions.